Serevent
The Food and Drug Administration (FDA) approved GlaxoSmithKline's Serevent in
1994 for the treatment of asthma-related symptoms. Subsequently, the FDA
approved Serevent as a treatment of chronic obstructive pulmonary heart disease.
Shortly after the drug's approval, concerns over Serevent's safety arose. A
number of participants in a 1996 clinical study of Serevent experienced severe
asthma episodes, some of which resulted in the individual's death. As a result,
the FDA requested GlaxoSmithKline to place a "black box" warning, the FDA's
highest cautionary label, on Serevent packaging and marketing materials by
December of 2003. Beyond making this request, the FDA has taken no further
action to address the safety concerns surrounding Serevent. GlaxoSmithKline has
refused to comply with the FDA's labeling request, thus the drug remains on the
market without the warnings deemed necessary by the federal government.
Despite the severe and fatal asthma attacks experienced by participants in the
1996 clinical studies of Serevent and the FDA's insistence that GlaxoSmithKline
feature black box warnings on Serevent, this drug remains on the market as a
potentially life-threatening drug. If you or a loved one has taken Serevent,
also known as Serevent Diskus and salmeterol xinafoate inhalation powder), we
will evaluate your
case absolutely free. If Serevent has injured you or a loved one, our legal
team will aggressively fight for your rights. You may be entitled to
compensation.
<< back
The information you obtain at this site is not, nor is it intended to be, legal advice. You should consult an attorney for individual advice regarding your own situation.
